Founder
Dr. Erik Wegener
Dr. Erik WegenerGeschäftsführer at Oxaphil GmbH
Phone
+49 155 65330061
Email
erik@oxaphil.com
Social Media

My notes to this person

No one else can see these notes.

Organization

Startups
Dresden, Germany
Oxaphil GmbHWe develop functional, high-performance materials based on poly(2-oxazolines) (POx): precise, scalable, and biocompatible. Our focus is on the production and application of next-generation solubilizers for active ingredients, cosmetic actives, and other demanding formulations. POx are versatile materials: they dissolve, stabilize, protect, and enable controlled release. Their modular chemistry allows us to develop tailored solutions for real formulation challenges, often with superior precision and performance compared to conventional alternatives. Our technology is based on a patented synthesis platform that enables us to produce POx with a defined structure, high purity, and scalable quantities. This opens up a powerful class of materials for industrial use – materials that have long been established in academic research but have been rarely available commercially. Oxaphil combines sound scientific expertise with a clear application focus. Our team combines backgrounds in polymer chemistry, formulation science, and technology transfer. In collaboration with partners, we transfer POx from the laboratory into real-world applications, from cosmetics to biotechnology to pharmaceuticals.

Innovations & Products

Polyoxazoline

Oxaphil develops and produces innovative [products] for pharmaceutical and cosmetic formulations as well as for coating various surfaces. Our products serve in particular as powerful solubilizers and formulation aids and offer a versatile alternative to established materials. We develop tailored materials for specific requirements and support partners from material selection to application.

Erik Wegener
Erik WegenerGeschäftsführerOxaphil GmbH

Hardware / Machinery, Research Result, Product Innovation, Material